MedTrace Logo

Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease

NCT06694558 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-06-11

No results posted yet for this study

Summary

This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.

Conditions

  • Chronic Kidney Disease(CKD)
  • Type 1 Diabetes (T1D)

Sponsors & Collaborators

  • Stanford University

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Rong M Zhang, MD · The Cleveland Clinic

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-12-30
Completion
2026-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06694558 on ClinicalTrials.gov